Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 1;58(3):382-387.
doi: 10.1093/rheumatology/key064.

Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus

Pedro L Carreira  1 , David A Isenberg  2
Affiliations
Review

Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus

Pedro L Carreira et al. Rheumatology (Oxford). .

Abstract

SLE has a complex pathogenesis, and multiple therapeutic targets have been discovered in recent years. In spite of belimumab being approved by the US Food and Drug Administration and the widespread use of rituximab, there have been many failed attempts to treat SLE successfully using biologic agents. In this review, we consider newer biologic approaches that might offer the hope of improving the outcome of SLE patients. These include the fully humanized anti-CD20 mAbs, PEGylated anti-CD40L, IFNα inhibitors, rigerimod and immune complexes blockade.

Keywords: FCγR; anti-CD20; anti-CD40L; biologic; dapirolizumab; interferon; lupus; obinutuzumab; ofatumumab; rigerimod.

PubMed Disclaimer

MeSH terms